Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Update

Vincerx Pharma, Inc. (NASDAQ:VINC) was the target of a large increase in short interest in the month of November. As of November 30th, there was short interest totalling 735,400 shares, an increase of 22.6% from the November 15th total of 600,000 shares. Based on an average trading volume of 607,900 shares, the short-interest ratio is presently 1.2 days.

Wall Street Analysts Forecast Growth

Separately, Leerink Partners reduced their target price on shares of Vincerx Pharma from $4.00 to $2.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th.

Vincerx Pharma Price Performance

VINC opened at $0.19 on Friday. The stock’s 50 day moving average price is $0.32 and its 200 day moving average price is $0.56. The stock has a market cap of $6.43 million, a P/E ratio of -0.19 and a beta of 1.48. Vincerx Pharma has a 12 month low of $0.18 and a 12 month high of $9.37.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of VINC. Vanguard Group Inc. grew its position in Vincerx Pharma by 29.9% in the 1st quarter. Vanguard Group Inc. now owns 666,995 shares of the company’s stock valued at $3,375,000 after buying an additional 153,575 shares in the last quarter. Marshall Wace LLP boosted its holdings in shares of Vincerx Pharma by 359.1% in the second quarter. Marshall Wace LLP now owns 328,533 shares of the company’s stock valued at $266,000 after acquiring an additional 256,967 shares in the last quarter. Finally, Armistice Capital LLC acquired a new position in shares of Vincerx Pharma during the second quarter valued at approximately $1,610,000. 44.02% of the stock is owned by institutional investors and hedge funds.

About Vincerx Pharma

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.